Related references
Note: Only part of the references are listed.Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction
Alan L. Pehrson et al.
CNS SPECTRUMS (2014)
Early and sustained improvement with vilazodone in adult patients with major depressive disorder: post hoc analyses of two phase III trials
Rakesh Jain et al.
CURRENT MEDICAL RESEARCH AND OPINION (2014)
Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: A potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism
Kristian Gaarn du Jardin et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2014)
Vortioxetine, but not escitalopram or duloxetine, reverses memory impairment induced by central 5-HT depletion in rats: Evidence for direct 5-HT receptor modulation
Jesper Borno Jensen et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2014)
The efficacy of extended-release levomilnacipran in moderate to severe major depressive disorder: secondary and post-hoc analyses from a randomized, double-blind, placebo-controlled study
Stuart A. Montgomery et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2014)
Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trials
Angelo Sambunaris et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2014)
Safety, tolerability, and efficacy of vortioxetine (Lu AA21004) in major depressive disorder: results of an open-label, flexible-dose, 52-week extension study
Mohammed Y. Alam et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2014)
Vilazodone in the treatment of major depressive disorder: efficacy across symptoms and severity of depression
Arif Khan et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2014)
Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder
Jean-Philippe Boulenger et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2014)
Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
L. Citrome
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2014)
A Phase III, Double-Blind, Placebo-Controlled, Flexible-Dose Study of Levomilnacipran Extended-Release in Patients With Major Depressive Disorder
Angelo Sambunaris et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2014)
Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study
David Bakish et al.
JOURNAL OF PSYCHIATRY & NEUROSCIENCE (2014)
Serotonergic Drugs for Depression and Beyond
Stephen M. Stahl et al.
CURRENT DRUG TARGETS (2013)
A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder
Atul R. Mahableshwarkar et al.
CURRENT MEDICAL RESEARCH AND OPINION (2013)
COGNITIVE DEFICITS AND FUNCTIONAL OUTCOMES IN MAJOR DEPRESSIVE DISORDER: DETERMINANTS, SUBSTRATES, AND TREATMENT INTERVENTIONS
Roger S. McIntyre et al.
DEPRESSION AND ANXIETY (2013)
Vortioxetine (Lu AA21004) 15 and 20 mg/day: open-label long-term safety and tolerability in major depressive disorder
G. Filippov et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2013)
Vortioxetine, a novel multimodal antidepressant, modulates GABA and glutamate neurotransmission via serotonergic mechanisms
A. Pehrson et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2013)
Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters-A rat microdialysis and electrophysiology study
Alan L. Pehrson et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2013)
A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder
Rakesh Jain et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2013)
Efficacy and Safety of Levomilnacipran Sustained Release in Moderate to Severe Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study
Stuart A. Montgomery et al.
JOURNAL OF CLINICAL PSYCHIATRY (2013)
Efficacy and Safety of Levomilnacipran Sustained Release 40 mg, 80 mg, or 120 mg in Major Depressive Disorder: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
Gregory M. Asnis et al.
JOURNAL OF CLINICAL PSYCHIATRY (2013)
Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice
Jean-Philippe Guilloux et al.
NEUROPHARMACOLOGY (2013)
Levomilnacipran (F2695), a norepinephrine-preferring SNRI: Profile in vitro and in models of depression and anxiety
A. L. Auclair et al.
NEUROPHARMACOLOGY (2013)
Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats
Arne Mork et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2013)
Occupancy of the Serotonin Transporter after Administration of Lu AA21004 and its Relation to Plasma Concentration in Healthy Subjects
Johan Areberg et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2012)
The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder
Carol R. Reed et al.
CURRENT MEDICAL RESEARCH AND OPINION (2012)
Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder
David S. Baldwin et al.
CURRENT MEDICAL RESEARCH AND OPINION (2012)
On assessing potential efficacy for vortioxetine in generalized anxiety disorder
David S. Baldwin et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2012)
A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD)
David S. Baldwin et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2012)
A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder
Cornelius Katona et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2012)
A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder
Enric Alvarez et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2012)
A Randomized, Double-Blind, Placebo-Controlled 8-Week Trial of the Efficacy and Tolerability of Multiple Doses of Lu AA21004 in Adults With Major Depressive Disorder
Neven Henigsberg et al.
JOURNAL OF CLINICAL PSYCHIATRY (2012)
A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder
Jean-Philippe Boulenger et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2012)
Pharmacological Effects of Lu AA21004: A Novel Multimodal Compound for the Treatment of Major Depressive Disorder
A. Mork et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scale
David V. Sheehan et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2011)
Vilazodone: Clinical Basis for the US Food and Drug Administration's Approval of a New Antidepressant
Thomas P. Laughren et al.
JOURNAL OF CLINICAL PSYCHIATRY (2011)
Exploratory Analyses of Efficacy Data From Major Depressive Disorder Trials Submitted to the US Food and Drug Administration in Support of New Drug Applications
Ni A. Khin et al.
JOURNAL OF CLINICAL PSYCHIATRY (2011)
A Randomized, Double-Blind, Placebo-Controlled, 8-Week Study of Vilazodone, a Serotonergic Agent for the Treatment of Major Depressive Disorder
Arif Khan et al.
JOURNAL OF CLINICAL PSYCHIATRY (2011)
Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder
Benny Bang-Andersen et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
The Small Specific Effects of Antidepressants in Clinical Trials: What Do They Mean to Psychiatrists?
Michael E. Thase
CURRENT PSYCHIATRY REPORTS (2011)
Role of 5-HT3 Receptors in the Antidepressant Response
Cecile Betry et al.
PHARMACEUTICALS (2011)
Defining and Measuring Functional Recovery from Depression
Tracy L. Greer et al.
CNS DRUGS (2010)
The well of novel antidepressants: running dry
Pierre Blier
JOURNAL OF PSYCHIATRY & NEUROSCIENCE (2010)
Vilazodone, a novel dual-acting serotonergic antidepressant for managing major depression
Arif Khan
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?
Stuart A. Montgomery et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2009)
Evidence for Efficacy and Tolerability of Vilazodone in the Treatment of Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial
Karl Rickels et al.
JOURNAL OF CLINICAL PSYCHIATRY (2009)
Early Improvement in the First 2 Weeks as a Predictor of Treatment Outcome in Patients With Major Depressive Disorder: A Meta-Analysis Including 6562 Patients
Armin Szegedi et al.
JOURNAL OF CLINICAL PSYCHIATRY (2009)
The 5-HT7 receptor and disorders of the nervous system: an overview
Peter B. Hedlund
PSYCHOPHARMACOLOGY (2009)
The importance of functional impairment to mental health outcomes: A case for reassessing our goals in depression treatment research
Patrick E. McKnight et al.
CLINICAL PSYCHOLOGY REVIEW (2009)
Efficacy of Second Generation Antidepressants in Late-Life Depression: A Meta-Analysis of the Evidence
J Craig Nelson et al.
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY (2008)
Difference in treatment outcome in outpatients with anxious versus nonanxious depression: A STAR*D report
Maurizio Fava et al.
AMERICAN JOURNAL OF PSYCHIATRY (2008)
Selective publication of antidepressant trials and its influence on apparent efficacy
Erick H. Turner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: An 8-week, double-blind, placebo-controlled trial
Joel Raskin et al.
AMERICAN JOURNAL OF PSYCHIATRY (2007)
Projections of global mortality and burden of disease from 2002 to 2030
Colin D. Mathers et al.
PLOS MEDICINE (2006)
Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application
MJ Millan
PHARMACOLOGY & THERAPEUTICS (2006)
Remission in depression: definition and initial treatment approaches
JA Israel
JOURNAL OF PSYCHOPHARMACOLOGY (2006)
Estimating the prevalence and impact of antidepressant-induced sexual dysfunction in 2 European countries: A cross-sectional patient survey
VSL Williams et al.
JOURNAL OF CLINICAL PSYCHIATRY (2006)
A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder
GI Papakostas et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2006)
How should remission from depression be defined? The depressed patient's perspective
M Zimmerman et al.
AMERICAN JOURNAL OF PSYCHIATRY (2006)
Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder
RA Hansen et al.
ANNALS OF INTERNAL MEDICINE (2005)
Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone
ZA Hughes et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2005)
Antidepressant-related adverse effects impacting treatment compliance: Results of a patient survey
AK Ashton et al.
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL (2005)
The epidemiology of major depressive disorder - Results from the National Comorbidity Survey Replication (NCS-R).
RC Kessler et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review
JR Geddes et al.
LANCET (2003)
Is there a role for 5-HT1A agonists in the treatment of depression?
P Blier et al.
BIOLOGICAL PSYCHIATRY (2003)
Behavioral and neurochemical effects of 5-{4-[4-(5-cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl}-benzofuran-2-carboxamide (EMD 68843):: A combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine1A receptor partial agonist
ME Page et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Social functioning in depression:: A review
RMA Hirschfeld et al.
JOURNAL OF CLINICAL PSYCHIATRY (2000)
Share Paper
